Every material Form 8-K Actinium Pharmaceuticals, Inc. has filed with the SEC since June 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Actinium Pharmaceuticals said Matt David, M.D., began serving as chief financial officer on October 14, 2026, succeeding no one named in the filing. He previously was chief financial officer of CorMedix Inc. and will lead finance, accounting, capital markets and investor relations.
Dr. David commenced service as CFO and principal financial officer on October 14, 2026, under an offer letter dated September 30, 2026.
Offer terms include a $450,000 annual base salary, a 40% target annual bonus, and a $150,000 sign-on bonus.
He received an option on 250,000 shares and 325,000 restricted stock units under the 2026 Employment Inducement Award Plan, adopted by the Board on September 2, 2026 without stockholder approval.
NYSE Regulation accepted Actinium's compliance plan on August 12, 2026, and granted a plan period through November 27, 2027, to regain compliance with NYSE American continued listing standards. The company's common stock will keep trading on NYSE American during the plan period, but the company remains out of compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.
NYSE American notified the company on May 27, 2026, that it was not in compliance with Sections 1003(a)(ii) and (iii) of the Company Guide.
The company submitted its compliance plan on June 18, 2026, and NYSE Regulation accepted it in an August 12, 2026 letter.
The plan period runs through November 27, 2027, and the stock continues to trade under the symbol ATNM during this period.
If the company does not regain compliance or make progress consistent with the plan by the end of the period, NYSE Regulation may initiate delisting proceedings.
Actinium Pharmaceuticals submitted a compliance plan to NYSE American on June 18, 2026, describing actions management intends to take to restore compliance with listing standards. The exchange had notified the company on May 27, 2026 that its stockholders' equity was below the $4.0 million minimum required under Section 1003(a)(ii) of the NYSE American Company Guide, which applies after losses in three of four recent fiscal years.
June 18, 2026: Company submitted its compliance plan to NYSE American.
May 27, 2026: Company received the NYSE American notice regarding stockholders' equity.
Required minimum: stockholders' equity of $4.0 million or more under Section 1003(a)(ii).
The filing does not specify the individual actions management plans to take.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Actinium Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →